Gilead Sciences has temporarily stopped granting patients access to remdesivir, its experimental drug against the novel coronavirus that causes Covid-19, citing “overwhelming demand,” the company said Sunday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,